Establishment of an antibody specific for cancer-associated haptoglobin: A possible implication of clinical investigation

Kimihiro Nishino, Sayaka Koda, Naoya Kataoka, Shinji Takamatsu, Miyako Nakano, Shun Ikeda, Yuka Kamamatsu, Koichi Morishita, Kenta Moriwaki, Hidetoshi Eguchi, Eiko Yamamoto, Fumitaka Kikkawa, Yasuhiko Tomita, Yoshihiro Kamada, Eiji Miyoshi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We previously found that the serum level of fucosylated haptoglobin (Fuc- Hpt) was significantly increased in pancreatic cancer patients. To delineate the mechanism underlying this increase and develop a simple detection method, we set out to generate a monoclonal antibody (mAb) specific for Fuc-Hpt. After multiple screenings by enzyme-linked immunosorbent assay (ELISA), a 10-7G mAb was identified as being highly specific for Fuc-Hpt generated in a cell line as well as for Hpt derived from a pancreatic cancer patient. As a result from affinity chromatography with 10-7G mAb, followed by lectin blot and mass spectrometry analyses, it was found that 10-7G mAb predominantly recognized both Fuc-Hpt and prohaptoglobin (proHpt), which was also fucosylated. In immunohistochemical analyses, hepatocytes surrounding metastasized cancer cells were stained by the 10-7G mAb, but neither the original cancer cells themselves nor normal hepatocytes exhibited positive staining, suggesting that metastasized cancer cells promote Fuc-Hpt production in adjacent hepatocytes. Serum level of Fuc-Hpt determined with newly developed ELISA system using the 10-7G mAb, was increased in patients of pancreatic and colorectal cancer. Interestingly, dramatic increases in Fuc-Hpt levels were observed at the stage IV of colorectal cancer. These results indicate that the 10-7G mAb developed is a promising antibody which recognizes Fuc-Hpt and could be a useful diagnostic tool for detecting liver metastasis of cancer.

Original languageEnglish
Pages (from-to)12732-12744
Number of pages13
JournalOncotarget
Volume9
Issue number16
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Haptoglobins
Monoclonal Antibodies
Antibodies
Pancreatic Neoplasms
Neoplasms
Hepatocytes
Colorectal Neoplasms
Enzyme-Linked Immunosorbent Assay
Liver Neoplasms
Serum
Affinity Chromatography
Lectins
Mass Spectrometry
Staining and Labeling
Neoplasm Metastasis
Cell Line

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Nishino, K., Koda, S., Kataoka, N., Takamatsu, S., Nakano, M., Ikeda, S., ... Miyoshi, E. (2018). Establishment of an antibody specific for cancer-associated haptoglobin: A possible implication of clinical investigation. Oncotarget, 9(16), 12732-12744. https://doi.org/10.18632/oncotarget.24332

Establishment of an antibody specific for cancer-associated haptoglobin : A possible implication of clinical investigation. / Nishino, Kimihiro; Koda, Sayaka; Kataoka, Naoya; Takamatsu, Shinji; Nakano, Miyako; Ikeda, Shun; Kamamatsu, Yuka; Morishita, Koichi; Moriwaki, Kenta; Eguchi, Hidetoshi; Yamamoto, Eiko; Kikkawa, Fumitaka; Tomita, Yasuhiko; Kamada, Yoshihiro; Miyoshi, Eiji.

In: Oncotarget, Vol. 9, No. 16, 01.01.2018, p. 12732-12744.

Research output: Contribution to journalArticle

Nishino, K, Koda, S, Kataoka, N, Takamatsu, S, Nakano, M, Ikeda, S, Kamamatsu, Y, Morishita, K, Moriwaki, K, Eguchi, H, Yamamoto, E, Kikkawa, F, Tomita, Y, Kamada, Y & Miyoshi, E 2018, 'Establishment of an antibody specific for cancer-associated haptoglobin: A possible implication of clinical investigation', Oncotarget, vol. 9, no. 16, pp. 12732-12744. https://doi.org/10.18632/oncotarget.24332
Nishino, Kimihiro ; Koda, Sayaka ; Kataoka, Naoya ; Takamatsu, Shinji ; Nakano, Miyako ; Ikeda, Shun ; Kamamatsu, Yuka ; Morishita, Koichi ; Moriwaki, Kenta ; Eguchi, Hidetoshi ; Yamamoto, Eiko ; Kikkawa, Fumitaka ; Tomita, Yasuhiko ; Kamada, Yoshihiro ; Miyoshi, Eiji. / Establishment of an antibody specific for cancer-associated haptoglobin : A possible implication of clinical investigation. In: Oncotarget. 2018 ; Vol. 9, No. 16. pp. 12732-12744.
@article{54b2d316379a4c78b163d96a3e80a293,
title = "Establishment of an antibody specific for cancer-associated haptoglobin: A possible implication of clinical investigation",
abstract = "We previously found that the serum level of fucosylated haptoglobin (Fuc- Hpt) was significantly increased in pancreatic cancer patients. To delineate the mechanism underlying this increase and develop a simple detection method, we set out to generate a monoclonal antibody (mAb) specific for Fuc-Hpt. After multiple screenings by enzyme-linked immunosorbent assay (ELISA), a 10-7G mAb was identified as being highly specific for Fuc-Hpt generated in a cell line as well as for Hpt derived from a pancreatic cancer patient. As a result from affinity chromatography with 10-7G mAb, followed by lectin blot and mass spectrometry analyses, it was found that 10-7G mAb predominantly recognized both Fuc-Hpt and prohaptoglobin (proHpt), which was also fucosylated. In immunohistochemical analyses, hepatocytes surrounding metastasized cancer cells were stained by the 10-7G mAb, but neither the original cancer cells themselves nor normal hepatocytes exhibited positive staining, suggesting that metastasized cancer cells promote Fuc-Hpt production in adjacent hepatocytes. Serum level of Fuc-Hpt determined with newly developed ELISA system using the 10-7G mAb, was increased in patients of pancreatic and colorectal cancer. Interestingly, dramatic increases in Fuc-Hpt levels were observed at the stage IV of colorectal cancer. These results indicate that the 10-7G mAb developed is a promising antibody which recognizes Fuc-Hpt and could be a useful diagnostic tool for detecting liver metastasis of cancer.",
author = "Kimihiro Nishino and Sayaka Koda and Naoya Kataoka and Shinji Takamatsu and Miyako Nakano and Shun Ikeda and Yuka Kamamatsu and Koichi Morishita and Kenta Moriwaki and Hidetoshi Eguchi and Eiko Yamamoto and Fumitaka Kikkawa and Yasuhiko Tomita and Yoshihiro Kamada and Eiji Miyoshi",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.24332",
language = "English",
volume = "9",
pages = "12732--12744",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "16",

}

TY - JOUR

T1 - Establishment of an antibody specific for cancer-associated haptoglobin

T2 - A possible implication of clinical investigation

AU - Nishino, Kimihiro

AU - Koda, Sayaka

AU - Kataoka, Naoya

AU - Takamatsu, Shinji

AU - Nakano, Miyako

AU - Ikeda, Shun

AU - Kamamatsu, Yuka

AU - Morishita, Koichi

AU - Moriwaki, Kenta

AU - Eguchi, Hidetoshi

AU - Yamamoto, Eiko

AU - Kikkawa, Fumitaka

AU - Tomita, Yasuhiko

AU - Kamada, Yoshihiro

AU - Miyoshi, Eiji

PY - 2018/1/1

Y1 - 2018/1/1

N2 - We previously found that the serum level of fucosylated haptoglobin (Fuc- Hpt) was significantly increased in pancreatic cancer patients. To delineate the mechanism underlying this increase and develop a simple detection method, we set out to generate a monoclonal antibody (mAb) specific for Fuc-Hpt. After multiple screenings by enzyme-linked immunosorbent assay (ELISA), a 10-7G mAb was identified as being highly specific for Fuc-Hpt generated in a cell line as well as for Hpt derived from a pancreatic cancer patient. As a result from affinity chromatography with 10-7G mAb, followed by lectin blot and mass spectrometry analyses, it was found that 10-7G mAb predominantly recognized both Fuc-Hpt and prohaptoglobin (proHpt), which was also fucosylated. In immunohistochemical analyses, hepatocytes surrounding metastasized cancer cells were stained by the 10-7G mAb, but neither the original cancer cells themselves nor normal hepatocytes exhibited positive staining, suggesting that metastasized cancer cells promote Fuc-Hpt production in adjacent hepatocytes. Serum level of Fuc-Hpt determined with newly developed ELISA system using the 10-7G mAb, was increased in patients of pancreatic and colorectal cancer. Interestingly, dramatic increases in Fuc-Hpt levels were observed at the stage IV of colorectal cancer. These results indicate that the 10-7G mAb developed is a promising antibody which recognizes Fuc-Hpt and could be a useful diagnostic tool for detecting liver metastasis of cancer.

AB - We previously found that the serum level of fucosylated haptoglobin (Fuc- Hpt) was significantly increased in pancreatic cancer patients. To delineate the mechanism underlying this increase and develop a simple detection method, we set out to generate a monoclonal antibody (mAb) specific for Fuc-Hpt. After multiple screenings by enzyme-linked immunosorbent assay (ELISA), a 10-7G mAb was identified as being highly specific for Fuc-Hpt generated in a cell line as well as for Hpt derived from a pancreatic cancer patient. As a result from affinity chromatography with 10-7G mAb, followed by lectin blot and mass spectrometry analyses, it was found that 10-7G mAb predominantly recognized both Fuc-Hpt and prohaptoglobin (proHpt), which was also fucosylated. In immunohistochemical analyses, hepatocytes surrounding metastasized cancer cells were stained by the 10-7G mAb, but neither the original cancer cells themselves nor normal hepatocytes exhibited positive staining, suggesting that metastasized cancer cells promote Fuc-Hpt production in adjacent hepatocytes. Serum level of Fuc-Hpt determined with newly developed ELISA system using the 10-7G mAb, was increased in patients of pancreatic and colorectal cancer. Interestingly, dramatic increases in Fuc-Hpt levels were observed at the stage IV of colorectal cancer. These results indicate that the 10-7G mAb developed is a promising antibody which recognizes Fuc-Hpt and could be a useful diagnostic tool for detecting liver metastasis of cancer.

UR - http://www.scopus.com/inward/record.url?scp=85042560216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042560216&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.24332

DO - 10.18632/oncotarget.24332

M3 - Article

AN - SCOPUS:85042560216

VL - 9

SP - 12732

EP - 12744

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 16

ER -